Spiess Bernhard E.'s Form 4 filing
Castle Biosciences Inc (CSTL) · filed Sep 7, 2021
- Accession no.
- 0001447362-21-000213
- Filed
- Sep 7, 2021
- Trade date
- Sep 2, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.17M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Spiess Bernhard E.CIK 0001782994 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2021 | Common Stock | MOption exerciseAcquired | +8,989 | $1.92 | +$17,258.88 | 22,551 | Direct | |
| Sep 2, 2021 | Common Stock | MOption exerciseAcquired | +6,412 | $2.39 | +$15,324.68 | 28,963 | Direct | |
| Sep 2, 2021 | Common Stock | SSaleDisposed | −8,038 | $75.24F2 | −$604,779.12 | 20,925 | Direct | |
| Sep 2, 2021 | Common Stock | SSaleDisposed | −5,889 | $76.14F3 | −$448,388.46 | 15,036 | Direct | |
| Sep 2, 2021 | Common Stock | SSaleDisposed | −1,474 | $77.29F4 | −$113,925.46 | 13,562 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2021 | Common Stock | MOption exerciseDisposed | −8,989 | $0.00 | $0 | 5,889 | Direct | |
| Sep 2, 2021 | Common Stock | MOption exerciseDisposed | −6,412 | $0.00 | $0 | 2,304 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $74.59 to $75.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $75.60 to $76.45, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $76.70 to $77.63, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.